Wednesday, July 8, 2026

Drug profile · INN

sebetralstat

sebetralstat (EKTERLY) is an FDA-listed pharmaceutical active ingredient. Associated with Kalvista Pharmaceuticals (Ireland) Limited. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved Blood and blood forming organs (B06) B06AC08
US status approved
Patents linked 10
Pipeline programs 0
News articles 0
Drug details — sebetralstat
US status
approved
Class
Blood and blood forming organs (B06)
Route
ORAL
Patents
10
Programs
0
Data quality
0.89

Quick answer

sebetralstat (EKTERLY) is an FDA-listed pharmaceutical active ingredient. Associated with Kalvista Pharmaceuticals (Ireland) Limited. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN sebetralstat
Brand EKTERLY
Therapeutic class Blood and blood forming organs (B06)
Route ORAL
Formulation TABLET
ATC code B06AC08

Approval history

Authority Status Date
FDA approved
EMA approved

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)
  1. US 11739068

    Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11234939

    Dosage forms comprising a plasma kallikrein inhibitor

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11230537

    Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11198691

    N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11084809

    N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11001578

    N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 10611758

    N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 10478409

    Pharmaceutical compositions

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 10364238

    N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 9533987

    Heterocyclic derivates

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is sebetralstat?

sebetralstat (EKTERLY) is an FDA-listed pharmaceutical active ingredient. Associated with Kalvista Pharmaceuticals (Ireland) Limited. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for sebetralstat?

EKTERLY is a marketed brand name for sebetralstat. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sebetralstat?

sebetralstat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.